Supplementary Data — Adintrevimab for COVID-19: real-time meta analysis of 2 studies

@CovidAnalysis, December 2025, Version 1V1
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] death 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PrEP Ison (DB RCT) 50% 0.50 [0.13-1.99] death 3/1,001 6/1,001 EVADE PrEP Ison (DB RCT) 84% 0.16 [0.02-1.34] death 1/752 6/728 EVADE PrEP Ison (DB RCT) 84% 0.16 [0.02-1.34] hosp. 1/752 6/728 EVADE PrEP Ison (DB RCT) 70% 0.30 [0.16-0.56] symp. case 12/752 39/728 EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] death 0/240 1/241 EVADE PEP Ison (DB RCT) 80% 0.20 [0.01-4.15] death 0/240 2/241 EVADE PEP Ison (DB RCT) 80% 0.20 [0.01-4.15] hosp. 0/175 2/176 EVADE PEP Ison (DB RCT) 75% 0.25 [0.07-0.88] symp. case 3/175 12/176 Adintrevimab COVID-19 outcomes c19early.org December 2025 Favors adintrevimab Favors control
Fig. S1. All outcomes.